Drug major Ranbaxy Laboratories on Thursday reported a consolidated net profit of Rs 754.13 crore for the third quarter ended September 30, 2012.
The company had posted a net loss of Rs 464.58 crore for the quarter ended September 30, 2011, Ranbaxy Laboratories said in a statement.
Net profit includes tax, minority interest and share in loss of associate, it added.
Consolidated sales of the company stood at Rs 2,651.39 crore for the quarter under consideration as against Rs 2,023.22 crore for the corresponding period previous fiscal.
Commenting on the results Ranbaxy CEO and MD Arun Sawhney said: "Ranbaxy's business performance continued to strengthen as planned even in a volatile regulatory and business environment as our focus on key markets, improvement in manufacturing, R&D productivity and heightened level of cost consciousness helped our strong performance."
The company is confident that these measures will help further strengthen its base business, he added.